Company intelligence / Profile preview

CathWorks

Newport Beach, California, United Statescath.works ↗

Ownership: Private
Employees: ~83
Development stage: Commercial

Overview

CathWorks’ FFRangio System is commercially available and has demonstrated excellent diagnostic performance compared to traditional invasive FFR wires. The system met its primary endpoint in the PROVISION trial and completed enrollment in the landmark ALL-RISE global randomized controlled trial with over 1,900 patients across multiple continents. Clinical outcomes studies have shown safety and efficacy for managing patients based on FFRangio results.

Therapeutic areas: Cardiovascular
Modalities: DeviceArtificial Intelligence-based diagnostic platform
Industry: Digital Health Medical Devices

Partnerships

Medtronic (strategic partnership with path toward acquisition announced)Medtronic (Co-promotion agreement also noted in recent years.)

Beyond the preview

Go deeper on CathWorks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CathWorks.

Explore the full profile